600 mg AZD7442 IV + 600mg placebo IV
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (COVID-19)
Conditions
Coronavirus Disease 2019 (COVID-19)
Trial Timeline
Dec 3, 2021 → May 6, 2023
NCT ID
NCT05184062About 600 mg AZD7442 IV + 600mg placebo IV
600 mg AZD7442 IV + 600mg placebo IV is a phase 2 stage product being developed by AstraZeneca for Coronavirus Disease 2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT05184062. Target conditions include Coronavirus Disease 2019 (COVID-19).
What happened to similar drugs?
0 of 12 similar drugs in Coronavirus Disease 2019 (COVID-19) were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05184062 | Phase 2 | Completed |
Competing Products
20 competing products in Coronavirus Disease 2019 (COVID-19)